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Abstract: Nonviral gene delivery is now considered a promising alternative to viral vectors. 
Among nonviral gene delivery agents, polyethylenimine (PEI) has emerged as a potent candidate 
for gene delivery to the lung. PEI has some advantages over other polycations in that it combines 
strong DNA compaction capacity with an intrinsic endosomolytic activity. However, intracellular 
(mainly the nuclear membrane) and extracellular obstacles still hamper its efﬁ  ciency in vitro 
and in vivo, depending on the route of administration and the type of PEI. Nuclear delivery has 
been increased by adding nuclear localization signals. To overcome nonspeciﬁ  c interactions 
with biological ﬂ  uids, extracellular matrix components and nontarget cells, strategies have been 
developed to protect polyplexes from these interactions and to increase target speciﬁ  city and 
gene expression. When gene delivery into airway epithelial cells of the conducting airways is 
necessary, aerosolization of complexes seems to be better suited to guarantee higher transgene 
expression in the airway epithelial cells with lower toxicity than observed with either intra-
tracheal or intravenous administration. Aerosolization, indeed, is useful to target the alveolar 
epithelium and pulmonary endothelium. Proof-of-principle that PEI-mediated gene delivery has 
therapeutic application to some genetic and acquired lung disease is presented, using as genetic 
material either plasmidic DNA or small-interfering RNA, although optimization of formulation 
and delivery protocols and limitation of toxicity need further studies.
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Introduction
Gene therapy has become a promising strategy for the treatment of inheritable or 
acquired lung diseases that are currently considered incurable. The lung is an attrac-
tive target for gene therapy since it is easily accessible and represents the organ where 
lethal mendelian (eg, cystic ﬁ  brosis) and acquired (eg, cancer) diseases occur.
Viral vectors have been applied to deliver therapeutic genes into living cells, but 
their broad use is limited by the inability of repeated administration and the severe safety 
risks (Lehrman 1999; Liu and Muruve 2003), based upon their immunogenicity and 
their oncogenic potential (Thomas et al 2003; Cavazzana-Calvo and Fischer 2007).
In light of these concerns, nonviral gene delivery has emerged as a promising 
alternative. The use of synthetic nonviral vectors confers several advantages, due 
to their ease of preparation, puriﬁ  cation and chemical modiﬁ  cation. Moreover, 
they display high ﬂ  exibility regarding the size of the transgene delivered (Lollo 
et al 2000). However, nonviral carriers linked electrostatically with plasmid DNA 
encounter various barriers at the tissue and cellular level. First, positively charged 
complexes have to interact with the molecules of the extracellular matrix (included 
proteoglycans) and of the basal membranes. The following step is interaction with the 
plasma membrane via electrostatic interactions with anionic cell surface groups, such 
as proteoglycans. Endocytosis is then followed by routing though the endo-lysosomal Drug Design, Development and Therapy 2008:2 164
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compartments, release into the cytoplasm, migration into 
the nucleus, and ﬁ  nally deconsendation of the DNA into a 
transcribable form.
Among the ﬁ  rst nonviral vectors used, cationic liposomes 
have displayed limited efﬁ  ciency and high toxicity, due to 
high levels needed to overcome tissue and cellular constraints, 
although recent research has highlighted the possibility 
to optimize their formulation to promote gene expression 
in vivo without increasing cytotoxicity (Ding et al 2007). 
Nevertheless, the liposomal class of drug delivery agents has 
a dominant position in clinical practice today (Zhang et al 
2008). Liposomal products include anti-fungals (AmBisome, 
Abelcet), antineoplastics (DepoCyt, Doxil, DaunoXome, 
Myocet), and antivirals (Epaxal, Inﬂ  exal V).
For these reasons, research has focussed mainly on 
alternative nonviral vectors, including cationic polymers 
that have intrinsic properties that help to override the above 
mentioned barriers. In the last decade, the cationic polymer 
polyethylenimine (PEI) has received much attention for its 
interesting properties as a gene transfer agent. Given the vast 
application of PEI as a gene delivery agent, in this review we 
will describe the biophysical features of PEI, its biological 
properties in reference above all to the lung, and its eventual 
use in therapeutic applications to lung diseases.
Physico-chemical properties of PEI 
complexes and gene transfer 
efﬁ  ciency in vitro
The use of cationic polymers became popular after introduc-
tion of PEI by Behr and colleagues (Boussif et al 1995) to 
mediate delivery of DNA. This polymer is available mainly 
in either linear or branched forms (Figure 1), and differ-
ent commercially available PEIs in the range of 25,000 to 
800,000 Daltons have successfully been employed for in 
vitro and in vivo gene delivery of DNA either alone or as 
complex with additional components such as viral proteins 
and targeting moieties (Boussif et al 1995; Baker and Cotten 
1997; Baker et al 1997; Meunier-Durmort et al 1997). PEI is 
a versatile vector, since it has been used successfully for in 
vitro delivery of nucleic acids including small interfering 
RNA (siRNA) (Read et al 2005; Urban-Klein et al 2005; 
Grayson et al 2006), rybozymes (Aigner et al 2002; Merdan 
et al 2002), and oligonucleotides (Boussif et al 1995; Dheur 
et al 1999) in addition to plasmidic DNA. PEI differs from 
cationic lipids at several levels, including behavior inside 
the cell (Rejman et al 2006). For example, PEI polyplexes 
enter the cells via both clathrin- and caveole-dependent 
routes, whereas DOTAP lipoplexes enter only via the 
clathrin-dependent pathway (Rejman et al 2005). It is known 
that caveolae – mediated endocytosis does not result in traf-
ﬁ  cking of gene transfer agents to the lysosomal compartment, 
where degadation of DNA by nuclease may occur. This could 
be one of the reasons why PEI polyplexes have been shown 
to be more efﬁ  cient than cationic lipids in vitro (Huh et al 
2007), as well as in vivo (Bragonzi et al 1999).
Indeed, some characteristics featured by PEIs make them 
attractive and proﬁ  cient vehicles for gene delivery. First of 
all, PEI has a high cationic charge density, since every third 
atom is a potentially protonable amino nitrogen. Approxi-
mately 20% of the nitrogens of PEI are protonated under 
physiological conditions (Suh et al 1994; Tang and Szoka 
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Figure 1 Chemical structure of linear PEI, branched PEI and water-soluble lipopolymer 
(WSLP). Copyright © 2006. Reprinted with permission from Park TG, Jeong JH, Kim 
SW. 2006. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev, 
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1997). As a result, the polymer can change its ionization 
state over a broad pH range and, as a consequence, PEI has 
a high intrinsic endosomolytic activity as compared to other 
polycations, such as polylysine (Boussif et al 1995). Second, 
PEI is very efﬁ  cient in condensing plasmid DNA and siRNA, 
thus protecting polynucleotides from nuclease degradation 
(Ferrari et al 1999; Urban-Klein et al 2005).
Structural characteristics such as the molecular weight 
and the degree of branching influence the efficacy of 
PEI-derived nonviral vectors in mediating delivery of 
plasmid DNA and siRNAs. The molecular weight of PEI 
most suitable for gene transfer ranges between 5 and 25 kDa, 
as assessed on L929 murine ﬁ  broblasts. Higher molecular 
weights correlate with increased cytotoxicity, presumably 
due to aggregation of huge clusters of the cationic polymer 
on the outer cell membrane, which thereby induces necrosis 
(Fischer et al 1999). PEI with a molecular weight less than 
1.8 kDa shows almost no transfection but is less toxic to 
human endothelial cell-derived cell line EA.hy 926 (Godbey 
et al 1999a). A series of five poly[(ethylene imine)-
co-N-(2-hydroxyethyl-ethylene imine)] copolymers with 
similar molecular weights and different degrees of branching 
was established to study structure-function relationship 
with regard to physicochemical and biological properties as 
gene delivery systems. Higher branched polymers showed 
stronger complexation and condensation of DNA, formed 
smaller polymer/DNA complexes, and induced the expres-
sion of plasmids in 3T3 mouse ﬁ  broblasts to a higher extent 
than less branched polymers (Fischer et al 2002). However, 
other studies have shown that the application of small 
polyplexes reduces the transfection efﬁ  ciency in Neuro 2A, 
K562 and B16F10 cells, compared to the larger complexes, 
although this effect seems to be dependent on the cell line 
used (Ogris et al 1998, 2001). The presence of serum did not 
affect, or indeed slightly increased, the efﬁ  ciency of PEI 25 
kDa-mediated plasmid DNA delivery in COS-1 and Calu-3 
cells (Florea et al 2002). Similarly, the transfection efﬁ  ciency 
of a GFP-expressing plasmid was almost the same or even 
slightly increased when PEI 800 kDa-cholesterol was used 
in HeLa cells in the presence of serum at different N/P ratios 
(Chen et al 2007). No signiﬁ  cant difference in the expres-
sion of luciferase could be observed between 3T3 ﬁ  broblasts 
transfected with a low molecular weight PEI in the presence 
or in the absence of serum (Fischer et al 1999).
Efﬁ  cient delivery systems for therapeutic siRNAs have 
been demanded for clinical applications. The delivery 
systems should be designed to solve intrinsic problems of 
naked siRNA: the lack of stability in the blood stream and 
a low intracellular transfection efﬁ  ciency, even though the 
target compartment is the cytoplasm and not the nucleus. 
PEI/siRNA complexes have been shown to give robust 
reduction in target gene expression in several different 
cellular models (either in co-transfection experiments or 
in cells stably expressing a marker gene) (Read et al 2005; 
Urban-Klein et al 2005; Kim et al 2006a; Werth et al 2006) 
(Table 1). For instance, one study showed that noncovalent 
complexation of synthetic siRNAs with a commercially 
available linear low molecular weight PEI (JetPEI) 
determined a 60% decrease of luciferase activity in luciferase-
expressing SKOV-3 ovarian carcinoma cells even in the pres-
ence of serum in the culture medium, demonstrating that upon 
PEI-complexation, siRNA is stabilized and internalized by the 
cells where it exerts its full bioactivity. VEGF siRNA-PEG 
complexed with branched PEI 25 kDa showed greater stabil-
ity and higher silencing than naked siRNA in the presence of 
serum in human prostate carcinoma cells (PC-3) (Kim et al 
2006a). Direct comparison among different PEIs showed 
that branched PEI 25 kDa at N/P ratio of 6 and 8 displayed a 
very strong afﬁ  nity for siRNAs and mediated efﬁ  cient down-
regulation of luciferase in luciferase-expressing HR5-CL11 
cell line (a HeLa derivative), whereas nor branched PEI 
800 kDa neither linear PEI 22 kDa were able to exert this 
effect (Grayson et al 2006). Only polyplexes formed by PEI 
25 kDa and displaying small size (59–80 nm) and positive 
zeta potentials (almost 40 mV) were able to deliver siRNA, 
while linear PEI 22 KDa gave inconsistent results. These 
results suggest that the predictability of siRNA transfection 
is not straightforward and that variable transfection results 
might also occur with other PEI architectures.
Size and charge of PEI complexes 
and their relation to in vitro 
and in vivo activity
PEI/DNA complexes have been found to form toroid 
structures of 40–80 nm (Tang and Szoka 1997), as estimated 
by electron microscopy. The higher the N/P ratio the lower 
the size of PEI complexes. Atomic force microscopy (AFM) 
studies have revealed that the morphology of PEI complexes 
may have different structures depending on the level of 
saturation of DNA by PEI (Dunlap et al 1997). Complete 
condensates were rounded globular shaped (with the size 
of 20–40 nm), while unsaturated complexes ranged from 
bundled, folded loops of DNA sorrounding central cores to 
loose coils with isolated nodes of condensation. Complexes 
formed between a 22 nt double-stranded siRNA and PEI were Drug Design, Development and Therapy 2008:2 166
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spherical with a mean diameter of ∼41.5 nm as determined 
by AFM analysis. The absence of free siRNA molecule 
ends, as well as the absence of free siRNA molecules, indi-
cated the complete complexation of the siRNAs (Grzelinski 
et al 2006). In the same study, PEI complexes with DNA 
plasmids were somewhat larger (95 nm), indicating no direct 
correlation between the size of nucleic acids and the size 
of their complexes (while siRNA is 22 bp the plasmid is 
5000 bp). The small size (59–80 nm) of bioactive PEI/siRNA 
complexes was confirmed by dynamic light scattering 
(Grayson et al 2006).
The size and zeta-potential of PEI/DNA polyplexes 
were found not to be dependent on the molecular weight 
(2, 25, or 750 kDa) or geometry (linear versus branched) 
of PEI, but mainly on the nitrogen to phosphate (N/P) ratio 
used (Choosakoonkriang et al 2003). Florea and colleagues 
(Florea et al 2002) showed that the zeta potential of 
polyplexes (formed with branched 600–1000, 60, and 
25 kDa) in a low-salt envirnonment (10 mM HEPES) 
increased proportionally with higher PEI concentration, 
reaching a plateau at high N/P ratio. While the surface charge 
show this behavior, the size of linear PEI 22 kDa complexes 
formed in 5% glucose does not change with increasing 
N/P ratio, as shown in Figure 2 (Kichler et al 2002).
On the other hand, the size of the PEI/DNA particles is 
clearly dependent on the conditions used for the preparation 
of the formulations and the type of PEI. Whereas branched 
PEI 25 kDa gene vectors formulated in distilled water 
and 5% glucose were kinetically stable, having diameters 
of ∼98 and ∼89 nm respectively, PEI complexes formu-
lated in HBS (150 mM NaCl) were larger (∼153 nm) and 
slowly aggregating (Rudolph et al 2005b). Conversely, the 
surface charge, as assessed by zeta potential measurement, 
was less positive in the highest ion concentration medium 
(water: ∼56 mV; 5% glucose: ∼45 mV; HBS: ∼12 mV). Elec-
tron microscopy studies revealed homogeneous populations 
of nearly globuar particles in all the solvents used (Figure 3). 
Using linear PEI 22 kDa to complex DNA in high salt solution 
gives quite large particles ( 1 μm) that work exceedingly well 
in vitro (Boussif et al 1995). However, formulation with the 
Table 1 Selected examples of in vitro and in vivo efﬁ  cacy of PEI-mediated siRNAs
Target Formulation Cell lines/in vivo model Reference
Tumours
VEGF siRNAs-s-PEG/PEI Human prostate carcinoma 
cells (PC-3)
(Kim et al 
2006a)
VEGF siRNA/low molecular 
weight PEI
Human prostate carcinoma 
cells (PC-3)
(Werth et al 
2006)
VEGF-R2 siRNA/RGD-PEG-PEI Subcutaneous tumor 
xenograft formed by N2A 
neuroblastoma cells in nude 
mice (i.v.)
(Schiffelers et al 
2004)
HER-2 siRNA/linear low 
molecular weight PEI 
(JetPEI) 
SKOV-3 ovarian carcinoma 
cells Subcutaneous tumour 
xenograft formed by SKOV-3 
cells in athymic nude mice 
(i.p.)
(Urban-Klein 
et al 2005)
Pleiotrophin siRNA/linear low 
molecular weight PEI 
( JetPEI)
U87 glioblastoma cells 
Subcutaneous tumour 
xenograft formed by U87 
cells in athymic nude mice 
(i.p, s.c.) Orthotopic mouse 
glioblastoma model (i.c.)
(Grzelinski et al 
2006)
Viral infection
Inﬂ  uenza A 
nucleocapsid 
protein
JetPEI Inﬂ  uenza virus infection 
in C57Bl/6 mice (i.v.)
(Ge et al 2004)
Inﬂ  uenza A 
nucleocapsid 
protein
Nonacylated PEI Inﬂ  uenza virus infection 
in C57Bl/6 mice (i.v.)
(Thomas et al 
2005)
Notes: Routes of administration are indicated: i.c.: intracranial; i.p.: intraperitoneal; i.t.: intratechal; s.c.: subcutaneous.
Abbreviation: VEGF, vascular endothelial growth factor.Drug Design, Development and Therapy 2008:2 167
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same linear PEI 22 kDa in an equi-osmotic but salt-free solution 
of 5% glucose produces particles with mean size ranging 
between 30 and 60 nm (Goula et al 1998b) (Figure 3).
A correlation between complexes size and transfection 
efﬁ  ciency in vitro has been shown (Wightman et al 2001). 
Linear PEI 22 kDa transfected murine neuroblastoma 
Neuro2a and C-26 colon carcinoma cells more efﬁ  ciently, 
as compared to branched PEI 800 kDa and PEI 25 kDa 
complexes, when formulated in high salt medium. More over, 
both branched and linear PEIs generated in salt-free 5% glucose 
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Figure 2 Zeta potential (A) and size (B) of non-PEGylated (•) and PEGylated (•) linear PEI 22 kDa complexes prepared in 5% glucose at different N/P ratios were measured 
using a Malvern Zetasizer. Note that the grafting with PEG residues allows to partially shield the surface charge of the polyplexes. The size of the particles generated with the 
PEI-PEG conjugate at N/P above 3 was slightly bigger than that observed with PEI (125 vs 100 nm). Copyright © 2002. Reprinted with permission from Kichler A, Chillon M, 
Leborgne C, et al 2002. Intranasal gene delivery with a polyethylenimine-PEG conjugate. J Control Release, 81:379–88.
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Figure 3 Electron microscopy of PEI/DNA complexes. PEI 25 kDNA complexes prepared in water (a) HBS (b) and 5% glucose (c) Copyright © 2005. Reprinted with permission 
from Rudolph C, Schillinger U, Ortiz A, et al 2005b. Aerosolized nanogram quantities of plasmid DNA mediate highly efﬁ  cient gene delivery to mouse airway epithelium. Mol Ther, 
12:493–501. Linear PEI 22 kDa complexes prepared in 150 mM NaCl (d) or 5% glucose (e) Copyright © 1998. Reprinted with permission from Goula D, Remy JS, Erbacher P, et al. 
1998b. Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Ther, 5:712–7.Drug Design, Development and Therapy 2008:2 168
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had reduced activity as compared to complexes generated in 
high-salt HBS. Only complexes generated with linear PEI 
22 kDa in high salt condition grew in size to reach ∼746 nm 
over 3 hours, indicating that high transfection efﬁ  ciency of 
PEI 22 kDa/DNA may be derived from its pronounced ability 
to aggregate in salt containing conditions.
To correlate the activity of PEIs in vivo with the activity 
observed in vitro, intravenous administration of polyplexes 
generated in different formulations (ie, high vs low salt) 
was carried out in BALB/C mice (Wightman et al 2001). 
Interestingly, PEI 22 kDa/DNA complexes generated in 
high salt were less active than the complexes formed in low 
salt (100-fold less). This apparent disagreement between 
in vitro and in vivo data was solved by demonstrating that 
when the salt concentration of linear PEI 22 kDa, previ-
ously formulated in low salt, was increased to 90% physi-
ological concentration these complexes rapidly aggregated. 
Overall, these data indicate that when complexes initially 
formulated in salt-free environment are introduced into the 
tail vein of mice the salt environment around the applied 
complexes would change rapidly determining an increase 
in their size. This speculation has been corroborated by 
other studies on intravenous administration in mice (see 
below).
A similar discrepancy between in vitro and in vivo 
data has been noted with a topical administration of 
PEI polyplexes to the lung. Intratracheal injection of 
TAT-PEG-PEI polyplexes in mice demonstrated differences 
of a ca. 600% higher transfection efﬁ  ciency compared to 
PEI which was not reﬂ  ected in the in vitro experiments in 
A549 cells (Kleemann et al 2005).
In conclusion, the multidimensional tissue structure of 
the lung and extracellular protein/enzyme network reveal 
difﬁ  culties in extrapolation of in vitro results to successful 
gene delivery into the complex lung systems.
Cytotoxicity in vitro
Unmodiﬁ  ed PEIs can induce cytotoxicity, often deﬁ  ned 
by assessing either the release of lactate dehydrogenase 
(LDH) or a decrease in the in vitro metabolic activity 
of cells (eg, MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay) (Fischer et al 
1999; Godbey et al 2001; Putnam et al 2001; Florea et al 
2002). The higher the N/P ratio and the DNA amount used 
for transfection, the higher the cytotoxicity of linear PEI 
25 kDa polyplxes, as assessed in various cell lines (HEK293T, 
COS-7, HeLa, NCCIT) (Huh et al 2007). Godbey and col-
leagues (2001) have shown that when complexes formed 
between branched PEIs (600 Da, 10 kDa, 25 kDa) and a 
GFP-expressing plasmid were used to transfect the endo-
thelial cell line EA.hy 926, the secreted levels of tissue-type 
plasminogen activator, plasminogen activator inhibitor type 1 
and von Willeband factor increased above the levels recorded 
in untreated cells. Moreover, there appeared to be two distinct 
types of cell death, resulting from the use of either free PEI 
(which acts within 2 h) or PEI/DNA complexes (which cause 
death 7–9 h after transfection). The immediate cell death has 
been linked to the membrane destabilizing activity of free 
PEI, which contributes to as much as 85% of the total PEI 
in the PEI/DNA complexes used for transfection (Clamme 
et al 2003a).
In contrast to high molecular weight PEI (1600 kDa), 
a low molecular weight PEI (10 kDa) with a low degree of 
branching was not cytotoxic in L929 mouse ﬁ  broblasts and 
ECV 304 endothelial cells at the concentrations useful for 
efﬁ  cient cell transfection (Fischer et al 1999), indicating 
that high cationic charge densities, a compact and highly 
branched structure as well as high molecular weights 
all negatively affect the biocompatibility of PEI. On the 
other hand, branched PEIs with different MWs (25, 60, 
and 600–1000 kDa) were shown to be comparable in their 
cytotoxic effect in COS-1 (green monkey ﬁ  broblasts) and 
in well-differentiated human submucosal airway epithelial 
cells (Calu-3), with a slightly more pronounced effect with 
PEI 25 kDa (Florea et al 2002).
The molecular mechanisms underlying immediate and 
delayed cytotoxicity following PEI gene transfer have been 
recently elucidated. Branched PEI 25 kDa and linear high 
molecular weight PEI (750 kDa) can both induce membrane 
damage and initiate apoptosis in three clinically relevant 
human cell lines (Jurkat T cells, umbilical vein endothelial 
cells, and THLE3 hepatocyte-like cells) (Moghimi et al 
2005). Phase I toxicity was deﬁ  ned as early necrotic-like 
changes (30 min) resulting from compromized membrane 
integrity, assessed by LDH release and phosphatidylserine 
translocation from the inner plasma membrane to the outer 
cell surface. Phase II toxicity (24 h) was due to activation of a 
mitochondrially mediated apoptotic program, resulting from 
PEI-induced channel formation in the outer mitochindrial 
membrane. These results conﬁ  rm a previous study which 
suggested 25 kDa PEI could be a pro-apoptotic agent, as 
evaluated by Hoechst 33258 staining in COS-1 and Calu-3 
cells (Florea et al 2002).
The concentration of branched PEI 25 kDa that was 
found to mediate RNA interference in HR5-CL11 cells 
was not cytotoxic and the relative cytotoxicities of the Drug Design, Development and Therapy 2008:2 169
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three PEI structures was 800 kDa branched PEI   22 kDa 
linear PEI   25 kDa branched PEI (Grayson et al 2006). 
These results are comparable to those reported by others 
with plasmid DNA, where low molecular weight branched 
PEI was shown to be less cytotoxic than high molecular 
weight branched PEI (Fischer et al 1999).
In the attempt to decrease PEI cytotoxicity, different 
strategies have been pursued (Park et al 2006) including 
PEI-grafted PEGs, water-soluble lipopolymers, and 
biodegradable PEIs. PEI-grafted PEGs (PEI-g-PEG) with 
different PEG grafying ratios were synthesized (Petersen 
et al 2002). In 3T3 ﬁ  broblasts, cell cytotoxicity (LDH assay) 
of PEI-g-PEG was greatly reduced and was independent of 
molecular weight of PEG but affected by the degree of PEG 
substitution. Despite PEGylation, all copolymers showed 
transfection efﬁ  ciency (luciferase levels) at least as high as 
homopolymer PEI. Furthermore, at higher N/P ratios, the 
copolymers turned out to be even more efﬁ  cient than PEI.
The water-soluble lipopolymer (WLSP) (Figure 1) was 
synthesized by conjugating cholesteryl chloroformate to 
a low molecular weight PEI (1.8 kDa) (Han et al 2001). 
The hydrophobic cholesterol moiety of WLSP enabled the 
polymer to form micelles in acqueous solution. WSLP/pDNA 
complexes were nontoxic to CT-26 colon adenocarcinoma 
and 293T human embryonic kidney transformed cells when 
formulated at the N/P ratio of 10 and below as determined 
by MTT assay. In contrast, PEI 25 KDa/DNA complexes 
were toxic to these cells. Erythrocytes aggregated when 
incubated with PEI 25 kDa/pCMV-Luc complexes at high 
DNA concentrations, but there was little aggregation with 
WSLP/DNA complexes. WSLP/pCMV-Luc complexes 
demonstrated higher transfection efficiency in both 
CT-26 and 293T cells compared to PEI 25 kDa- or PEI 
1.8 kDa-based formulations.
Biodegradable PEIs have been synthetized by cross-
linking low molecular weight PEI (0.8 kDa) with either 
PEG-bis-succinimidyl succinate (Ahn et al 2002) or disul-
ﬁ  de-containing crosslinkers, such as dithiobis(succinimidy
lproprionate) and dimethyl 3–3’-dithiobisproprionimidate 
(Gosselin et al 2001) and exhibited decreased cytotoxicity 
and improved transfection efficiencies. For example, 
viability (MTT assay) of 293T cells was over 80% for all 
the synthesized cross-linked PEG/PEI copolymers, whereas 
cell viability was around 40% with PEI 25 kDa (Ahn et al 
2002). The transfection efﬁ  ciency (β-gal assay) of these 
copolymers was three times that of the initial PEI 0.8 kDa. 
Novel biodegradable poly(ester amine)s (PEAs) based on 
polycaprolactone and different low molecular weight PEIs 
(0.6, 1.2, and 1.8 kDa) was prepared and characterized (Arote 
et al 2007). Upon incubation at 37 °C and at physiological 
pH, all PEAs showed typical degradation pattern where the 
susceptible ester linkages got hydrolyzed leading to forma-
tion of low molecular weight degradation products which are 
nontoxic in nature. PEAs were nontoxic to 293T, HepG2 and 
HeLa cells and increased luciferase levels in these cells up 
to 25-fold as compared with PEI 25 kDa.
Intracellular trafﬁ  cking of PEI 
complexes in vitro
Binding and uptake
It is generally accepted that interaction of polyplexes 
with cells is nonspeciﬁ  c and involves mainly electrostatic 
interactions between the positively charged complexes and 
the negatively charged cell surface, as showed in various 
cell types (3T3 mouse ﬁ  broblasts, HepG2 human hepato-
cytes, COS-7 simian kidney cells, HeLa human carcinoma 
cells, and MRC-5 human lung embryonic cells) (Boussif 
et al 1995). The positively charged DNA polyplexes 
can interact with negatively charged molecules such as 
glycosaminoglycans (GAGs). Heparan sulfate (HS) is an 
anionic GAG that is found in the extracellular space and on 
the surface of most cells, often in the structure of proteogly-
cans (PGs) (Kramer and Yost 2003). Unmodiﬁ  ed cationic 
complexes interact nonspeciﬁ  cally with negatively charged 
glycoproteins, HS and PGs (Behr 1994; Labat-Moleur et al 
1996; Mislick and Baldeschwieler 1996; Mounkes et al 
1998) located on the surface of cell membranes. A report 
suggests that the uptake of PEI polyplexes by HeLa cells 
occurs through actin-mediated phagocytosis as a result 
of the adhesion of polyplexes to syndecan PG molecules 
followed by their clustering in lipid rafts (Kopatz et al 
2004). However, the interactions between the positively 
charged DNA complexes and negatively charged cellular 
GAGs may hamper speciﬁ  c ligand-receptor interaction and 
extracellular GAGs or PGs may reduce the DNA delivery 
to the target cells.
Endocytosis (the vescicular uptake of extracellular 
macromolecules) has been established as the main mecha-
nism for the internalization of nonviral vectors into cells, with 
a size range of 100–200 nm (Khalil et al 2006). Kinetically, 
three modes of endocytosis can be deﬁ  ned: ﬂ  uid-phase, 
adsorptive, and receptor mediated endocytosis. While ﬂ  uid-
phase endocytosis refers to bulk uptake of solutes according 
to their concentration in the extracellular ﬂ  uid, in adsorp-
tive and receptor-mediated endocytosis, macromolecules Drug Design, Development and Therapy 2008:2 170
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are bound to the cell surface and concentrated before 
internalization. Endocytosis can also be classiﬁ  ed into two 
broad categories: phagocytosis (for the uptake of large 
particles), which is restricted to specialized mammalian 
cells, and pynosytosis (for the uptake of luid and solutes), 
which occurs in all cells. Although four morphologically 
distinct pynocytic pathways have been characterized 
(clathrin-mediated endocytosis, caveolae, macropynocytosis, 
and clathrin/caveolae-independent endocytosis), most 
pynocytic pathways involve receptor-ligand interactions.
Following their interaction with anionic surface molecules 
on the cell surface, polyplexes enter the cell predominantly 
via adsorptive endocytosis in EA.hy.926 endothelial cells 
(Godbey et al 1999b) or ﬂ  uid-phase endocytosis in L929 
mouse ﬁ  broblasts (Remy-Kristensen et al 2001). Both micros-
copy analysis and endocytosis-interfering drugs were used for 
demonstrating these pathways of internalization (Ogris et al 
2001; Remy-Kristensen et al 2001; Bieber et al 2002). Using 
colocalization with endocytic markers, Remy-Kristensen 
and colleagues have demonstrated that polyplexes formed 
between branched PEI 25 KDa and DNA enter the cells and 
accumulate within 10 min in endosomes that were about 
200 nm in diameter following a typical pinocytosis pathway 
(Remy-Kristensen et al 2001). A rapid accumulation of 
polyplexes in the lysosomal compartment, by endocytosis, 
has been showed using both subcellular fractionation and 
confocal/electron microscopy techniques in PaTu 8902 cells, 
derived from a human pancreatic adenocarcinoma (Bieber 
et al 2002).
Using endocytosis-interfering drugs, Rejman and 
colleagues (2005) has provided strong evidence that poly-
plexes are internalized both by clathrin-mediated and by 
caveolae-mediated endocytosis in A549 and HeLa cells. 
Moreover, they showed that only the caveolae-dependent 
route leads to effective transfection while the DNA contained 
in the polyplexes internalized by clathrin-mediated endocy-
tosis could not be released and was taken with the complex 
into the lysosomal compartment to be degraded. It has also 
been shown that the internalization pathway mediating 
successful transfection depended on both cell type and 
polyplex type applied (von Gersdorff et al 2006). The use 
of speciﬁ  c uptake inhibitors (chlorpromazine and ﬁ  lipin III) 
revelaed that in COS-7 cells the clathrin-dependent path-
way was dominant. In HUH-7 hepatocarcinoma cells, gene 
transfer by linear PEI 22 kDa was mainly dependent on the 
clathrin-dependent route, whereas transfection by branched 
PEI 25 kDa was mediated by both clathrin- and caveole/
lipid raft-dependent pathways. Finally, in HeLa cells, both 
pathway were involved, although the lipid-raft-dependent 
route was more relevant.
The intracellular fate of PEI polyplexes was studied in 
detail by using lactosylated PEI 25 kDa (Lac-PEI) in the 
human tracheal epithelial ΣCFTEo- cell line (Grosse et al 
2005). Electron microscopy studies showed that the cellular 
processing of complexes varied with their size and the poly-
cation derivative used: large complexes ( 200 nm) made 
with all polycationic vectors studied were internalized by 
macropinocytosis. In contrast, intermediate (100–200 nm) 
glycosylated polylysine and PEI complexes primarily entered 
through clathrin-coated pits. Complexes were than found 
in endosomal vesicles, accumulated in lysosomes or in 
vesicles near the nucleus. The population of small complexes 
( 100 nm) obtained with PEI derivatives were internalized 
through caveolae and pursued a trafﬁ  c pattern of potocytosis 
to the endoplasmic reticulum.
Although not studied in as much detail as PEI/DNA 
complexes, the nonspeciﬁ  c endocytosis via clathrin-coated 
pits is the likely mechanism of internalization of PEI/siRNA 
complexes. The complexes formed with branched PEI 25 kDa 
were smaller than 150 nm (Grayson et al 2006; Grzelinski 
et al 2006), which is considered the size limit for this route 
of internalization.
Endosomal escape
PEI, as a nonviral vector, combines a high membrane-
destabilizing potential with a high DNA condensing 
activity, thus protecting DNA from degradation and there-
fore increasing the probability that intact plasmid DNA 
will reach the nucleus (Klemm et al 1998; Zhang and 
Smith 2000). However, polyplexes should overcome the 
endosomal-lysosomal barrier. The “proton-sponge” hypoth-
esis, which has been postulated by Behr (1994), relates the 
intrinsic endosomolytic activity of PEI to its capacity to 
buffer the endosomal compartment, causing the osmotic 
swelling of the vescicle and its rupture with the releasing 
of the polyplexes into the cytoplasm. On the basis of this 
phenomenon, the fusion with lysosomes may thereby be 
prevented, circumventing DNA degradation by lysosomal 
DNAse activity. Membrane holes have been observed by 
electron microscopy and they were attributed to the direct 
interaction of branched PEI with the internal side of the 
endosomal membrane (Bieber et al 2002). While acidiﬁ  ca-
tion seems to facilitate vesicle rupture (Kichler et al 2001; 
Forrest and Pack 2002), the membrane damage occurred 
in a dose-dependent manner (Clamme et al 2003b) and 
was present even in the absence of acidiﬁ  cation when high Drug Design, Development and Therapy 2008:2 171
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molecular weight-branched PEI derivatives are used (Bieber 
et al 2002). A report directly supporting the “proton sponge 
hypothesis” demonstrates that increased PEI buffer capac-
ity results in endosomal Cl− entry because of H+/Cl− charge 
coupling, promoting osmotic swelling and endosome leak/
lysis, as shown in Chinese hamster ovary (CHO)-K1 cells 
(Sonawane et al 2003).
Interestingly, some experiments, which were carried 
out using 35S-DNA/branched PEI, have revealed that the 
endosomolitic activity may depend on the particle size, sug-
gesting that larger polyplexes entrapped in endosomes may 
facilitate endosomolysis (Boussif et al 1995; Ogris et al 1998; 
Wattiaux et al 2000; Blessing et al 2001), while the efﬁ  cient 
gene delivery mediated by small particles relies on the addi-
tion of endosomolytic compounds (Blessing et al 2001).
In the attempt to further improve gene delivery, sev-
eral virus-derived endosomolytic proteins or peptides 
were incorporated onto branched PEI/DNA polyplexes 
(Table 2). The membrane-active peptide JTS-1 (Gottschalk 
et al 1996; Sparrow et al 1998), the Haemophilus inﬂ  uenzae 
hemagglutinin-derived peptides (INF) (Lear and DeGrado 
1987; Plank et al 1994; Wolfert and Seymour 1998; Wagner 
1999) and GALA peptide (Subbarao et al 1987; Parente et al 
1990, 1990b) all assume a random coil structure at pH 7. 
Upon acidiﬁ  cation, a conformational transition occurs, which 
enables the subsequent interaction with the phospholipids 
membranes, resulting in pore formation or the induction 
of membrane fusion and/or lysis (Parente et al 1988). The 
membrane-active dimeric inﬂ  uenza peptide INF5 (Plank 
et al 1994) has been attached to both transferrin-branched 
PEI/DNA and branched PEI/DNA polyplexes, increasing 
transgene expression up to 10-fold (Kircheis et al 1997). 
However, the optimum expression levels observed were not 
signiﬁ  cantly higher than the maximum expression at high 
N/P ratios without INF5.
KALA peptide (Wyman et al 1997; Lee et al 2001) 
resembles the membranolytic activity of GALA with DNA 
condensing properties derived from the lysine residues 
(Wyman et al 1997). After site-speciﬁ  c mono-PEGylation, 
PEG-KALA was attached to the surface of branched PEI/
DNA polyplexes (Lee et al 2001). The PEGylation sterically 
prevented particle aggregation and increasing concentrations 
of either branched PEI or PEG-KALA led to an enhanced 
transfection efﬁ  ciency.
The tranfection potential of branched PEI 25 kDa/KALA 
complexes was evaluated in various cells in culture. In most 
cell lines (HeLa, C2C12 mouse myoblasts, 3T3 mouse 
ﬁ  broblasts, human Chang Liver cells) PEI/KALA exhibited 
tranfection efﬁ  ciencies higher then PEI 25 kDa (Min et al 
2006). The performance of PEI/KALA was tested in the C3 
subcutanetenous mouse tumor model. Luciferase plasmid 
DNA complexed with either PEI/KALA or PEI was directly 
injected in the tumor. The tumors injected with PEI/KALA/
DNA complexes showed 2.5–3.5-fold higher luciferase 
activity than those injected with PEI/DNA.
However, concerns have arisen about the high costs of 
peptide synthesis and the risk of immunogenic reactions. At 
the moment, since the DNA release from PEI polyplexes into 
the cytoplasm is sufﬁ  ciently supported by its own endosomo-
lytic activity, the usefulness of these endosome-destabilizing 
peptides is controversial.
Another approach consists of using HIV–1 virus trans-
activator protein (TAT) or its derivatives, which are know 
to be cell penetrating peptides (Jones 2007) with fusogenic 
properties (Martin and Rice 2007). Rudolph and colleagues 
(2003), using complexes formed between PEI and oligomers 
of the arginine-rich motif of the HIV-1 TAT protein, have 
demonstrated how they are capable of improving the trans-
fection efﬁ  ciency of PEI/DNA complexes in vitro in A549 
cells, although not in vivo after an intratracheal administra-
tion. Conversely, TAT-PEG-PEI 25 kDa polyplexes medi-
ated much lower levels of luciferase in A549 cells than PEI, 
while higher transfection efﬁ  ciencies for TAT-PEG-PEI were 
detected in mice upon intratracheal instillation (Kleemann 
et al 2005).
Interaction with cytosolic components 
and nuclear import
Once PEI/DNA complexes are released from the endosomal 
vesicles, they must reach the perinuclear region and enter 
the nucleus. Generally, plasmid DNA larger than 2000 bp, 
released from endosomes, remains nearly immobile within 
the viscous cytoplasm (Lukacs et al 2000) and is degraded 
by cytosolic nucleases (Lechardeur et al 1999; Pollard et al 
2001). Further, when isolated DNA is micro-injected into 
the cytoplasm of COS-7 cells, less than 0.1% of this DNA 
reaches the nucleus (Pollard et al 1998). PEI is able to prolong 
the survival of plasmid DNA in a dose dependent manner, 
facilitated by the complexation of DNA, without affecting 
nuclease activity itself (Pollard et al 1998, 2001).While 
Okuda and colleagues have suggested that cytosolic soluble 
proteins (protease sensitive) can induce DNA dissociation 
from PEI/DNA complexes (Okuda et al 2004), others have 
demonstrated that RNA can dissociate DNA from complexes 
in a dose- and polymer-dependent fashion (Bertschinger 
et al 2006; Huth et al 2006). RNA (in particular tRNA) is Drug Design, Development and Therapy 2008:2 172
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present in the cytoplasm at high concentrations and show high 
structural similarity to DNA. Data suggest that the release of 
DNA from polyplexes is primarly due to charge interaction 
but not sequence-dependent (Huth et al 2006).
Many evidences show that entire gene vector complexes 
are largely excluded from entry into nonmitotic nuclei (Itaka 
et al 2004; Grosse et al 2006; Huth et al 2006). Others have 
found PEI/plasmid DNA complexes inside the nucleus, albeit 
at low levels (Godbey et al 1999b; Grosse et al 2004). For 
example, for both lactosylated and unsubstituted PEI 25 kDa 
PEIs, nuclear localization was observed for less than 5% of 
intracellular complexes in an immortalized human tracheal 
epithelial cell line (ΣCFTE29o-) (Grosse et al 2004). Electron 
microscopy studies combined with in situ PCR and FISH 
performed in our laboratory in pneumocyte type II A549 cells 
show that PEI/DNA complexes are excluded from nuclei in 
intact cells while the plasmid is found inside isolated nuclei 
(Bifﬁ   et al unpublished results).
The mechanism by which plasmid DNA reaches the 
nuclear compartment is still poorly understood. The nuclear 
Table 2 Peptide-guided PEI-mediated gene delivery
Function Peptide Sequence Target organ/Cell lines Reference
Binding RGD-peptide ACDCRGDCFC CT-26 subcutaneous tumor in mice (Kim et al 2006b)
RGD-peptide ACRGDMFGCA HUVECs
N2A neuroblastoma cells
SVR-bag- 4 endothelial cells
N2A subcutaneous tumor in mice
(Schiffelers et al 2004)
Tet1 HLNILSTLWKYRC PC-12 neuron-like cells
3T3 murine ﬁ  broblasts
Primary rat astrocytes
Murine DRG neurons
(Park et al 2007)
CD13 ligand CNGRC HUVECs
HT-1080 human ﬁ  brosarcoma cells
H1299 non-small-cell lung cancer cells
H1299 subcutaneous tumor in athymic 
nude mice
(Moffatt et al 2005)
CD13 ligand CNGRC H1299 non-small-cell lung cancer cells
H1299 subcutaneous tumor in athymic 
nude mice
(Moffatt et al 2006)
Internalization IB1 CDSAFVTVDWGRSMSLC Calu – 3 (Florea et al 2003)
TAT GRKKRRQRRRPPQ COS-7
16HBE human bronchial cells
Primary nasal respiratory epithelium
(Rudolph et al 2003)
TAT GRKKKRRQRC A549 lung epithelial cells
Intratracheal instillation to the mouse 
lung
(Kleemann et al 2005)
KALA WEAKLAKALAKALA-
KHLAKALAKALKACEA
C2C12 mouse myoblasts
Human Chang Liver cells
3T3 mouse ﬁ  broblasts
HeLa
C3-subcutaneous mouse model
(Min et al 2006)
Endosome-
destabilizing
IFN5 GLFGAIAGFIENGWEG-
MIDGWYG
H225 human melanoma cells (Kircheis et al 1997)
KALA WEAKLAKALAKALA-
KHLAKALAKALKACEA
293T cells (Lee et al 2001)
Nuclear 
import
SV40-large T 
antigen
PKKKRKVEDPYC 3T3 murine ﬁ  broblasts
HeLa carcinoma cells
BNL CL.2 murine hepatocytes
Murine DRG neurons
Human macrophages
(Zanta et al 1999)
Abbreviations: DRG, dorsal root ganglion; HUVECs, human umbilical vein endhotelial cells.Drug Design, Development and Therapy 2008:2 173
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envelope is perforated by nuclear pore complexes (NPC), 
each of which assembles 8 smaller diffusion channels to 
allow macromolecules with an upper size limit of 50 kDa to 
diffuse freely (Talcott and Moore 1999) and a large channel 
for signal-mediated transport of macromolecules larger than 
50 kDa (Böttger et al 1998), which can expand to an upper 
diameter of 26 nm (8.0 × 106 Da), depending on the species 
and the metabolic state of the cell (Lungwitz et al 2005). 
Therefore, the transfection efﬁ  ciency is largely inﬂ  uenced 
by both the polyplexes size (Kreiss et al 1999) and plasmid 
copy number (Walker et al 2004). PEI/DNA complexes, 
which form particles within the 100–200 nm range, are thus 
excluded from nuclear entry through the NPC.
For active transport through the pore, a nuclear localiza-
tion signal (NLS) is required (Tachibana et al 2001). A NLS 
is typically composed of clusters of four or more basic ami-
noacids ﬂ  anked by α-helix breakers proline or glycine. Each 
NLS can interact with importin α which therefore becomes 
able to interact with importinα. This ternary complex can be 
uptaken through the nuclear pore by an energy-dependent 
mechanism (Pouton 1998).
Grosse and colleagues, using the human tracheal epithe-
lial cell line ©CFTE29o-, have shown that the nuclear import 
either of pDNA/PEI or of pDNA/lactose-PEI increases 
when the cells are undergoing mitosis (Grosse et al 2004). 
These results are consistent with those reported by Brunner 
and colleagues using transferrin-PEI (Brunner et al 2000; 
Brunner et al 2002) and by other groups with unconjugated 
PEIs (Remy-Kristensen et al 2001; Mannisto et al 2005, 
2007). Branched PEI 25 KDa-mediated transfection seems 
to be more dependent on the cell mitosis than that mediated 
by linear PEI 22 kDa (Brunner et al 2002).
On the contrary, it has been shown that many cells are 
still able to be transfected when growth-arrested (Pollard 
et al 1998; Godbey et al 1999b; Brunner et al 2002; Oh 
et al 2002). While in the former case, this is due to a passive 
nuclear importation during mitosis, mechanisms of transfec-
tion of mitotically quiescent cells are still indeciphered. This 
property could be another interesting feature of PEIs in view 
of gene transfer to the airway epithelium, whose half life has 
been shown to be more than 100 days (Blenkinsopp 1967).
In order to increase the nuclear import of DNA com-
plexed by PEI, Zanta and colleagues (1999) developed a 
CMV-luciferase construct containing a single, covalently 
linked SV40 large T-antigen NLS (Table 2). In this system, 
the luciferase reporter gene was capped on both ends with an 
ODN hairpin structure, increasing resistance to exonucleases 
up to 25-fold and complexed to branched PEI 25 kDa or linear 
PEI 22 kDa. The transfection efﬁ  ciency of these vectors in 
3T3 and HeLa cells was 100–1,000-fold higher (even at low 
DNA concentration) than that observed when no NLS or a 
mutated NLS was used.
All together, these data support the notion that plasmid 
DNA, in its free form or still complexed with PEI, enters the 
nucleus either in the mitotic phase or in post-mitotic nuclei. 
This brings concerns about the toxicity of PEI at the level of 
whole gene expression (see above).
Interestingly, it has been demonstated in acellular systems 
that transcription is not impaired when PEI is closely attached 
to the template DNA (Bieber et al 2002) and that transcrip-
tion inhibition was observed when plasmid DNA was either 
loosely (N/P   5) or tightly condensed (N/P   15) (Honoré 
et al 2005). It is then of interest that the ratios allowing the 
most efﬁ  cient transcription (5–15) are also those allowing the 
most efﬁ  cient transfection rates in vitro (Boussif et al 1995; 
Ogris et al 1998; Pollard et al 1998) and in vivo (Boussif 
et al 1995; Bragonzi et al 2000).
In vivo transfection of lung by PEIs
In recent years it has been shown that PEI is a good vehicle 
for plasmidic DNA and siRNAs delivery in vivo after lung 
instillation (Ferrari et al 1997; Bragonzi et al 2000), kid-
ney perfusion (Boletta et al 1997), intracerebral injection 
(Abdallah et al 1996), or systemic delivery to the lung (Goula 
et al 1998a; Bragonzi et al 1999; Thomas et al 2005) or to 
the liver (Chemin et al 1998). In this section we will discuss 
those parameters which inﬂ  uence PEI-mediated gene transfer 
in vivo, with particular emphasis on the lung.
Impact of routes of administration 
and biophysical parameters
The lung is an attractive target for gene therapy interventions 
and a variety of approaches such as intravenous, intranasal, 
intratracheal instillation or aerosol delivery have been utilized 
to target genes to the airways. PEI has been shown to be a 
suitable vehicle for gene transfer into lung epithelial cells in 
vivo (mouse and rabbit) with higher efﬁ  ciency than cationic 
lipids (Lemkine and Demeneix 2001; Bragonzi and Conese 
2002). Recently, aerosolization of PEI 25 kDa was shown 
to be of equal efﬁ  ciency as compared to the cationic lipid 
GL67, a gold standard for cystic ﬁ  brosis gene therapy, in the 
sheep (McLachlan et al 2007). High transfection efﬁ  ciency 
of PEI as compared with cationic lipids might be ascribed to 
its high intrinsic endosomolytic activity because of a strong 
buffer capacity at virtual any pH (see above). However, 
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hypothesis) is applicable following in vivo gene transfer is 
less clear in view of likely dilutional effects, due to airway 
surface liquid if topical administration is to be considered, 
as well as potential toxicities of the polymer that restrict 
local concentrations.
Intratracheal instillation of vectors into mouse lungs is 
still extensively used as a preclinical model to study vector 
efﬁ  cacy, toxicity, and the action of delivered transgenes. 
Unfortunately, intratracheal instillation can hardly be envis-
aged to be a practical administration route for human appli-
cations and therefore, the aerosolization seems to offer an 
optimal noninvasive means of targeting the lung (Densmore 
2006). The mode of gene vector application to the lung, ie, 
aerosol delivery vs direct instillation, exerts a pronounced 
effect on the gene transfer efﬁ  ciency. Rudolph and colleagues 
(2005b) demonstrated that aerosolized nanogram quantities 
of DNA complexed to PEI yielded transfection levels 1 
order of magnitude higher than microgram quantities of 
DNA applied directly to the lungs of mice via intratracheal 
intubation.
It must be said that the effects of the physicochemi-
cal properties of polyplexes on biological phenomena and 
transport processes are not yet fully understood and many 
efforts have done to elucidate the role of factors such as the 
polyplexes formulation, the solvent used and the polymer 
structure and pourity. The formulation of polyplexes, which 
is generally expressed in terms of N/P ratio, plays an impor-
tant role in the transfection efﬁ  ciency. PEI 25 kDa/DNA 
complexes of N/P ratios at 1,2, and 4 did not show luciferase 
activity in the lung following an intratracheal administration, 
whereas the transfection efﬁ  ciency was enhanced by increas-
ing the N/P ratio at values higher than 6 (Rudolph et al 2000). 
Formulation of complexes at N/P ratios  6 results in particles 
which bear negative or just slightly positive charges that are 
not able to arrange distinct cell adhesion and subsequent 
endocytosis. These ﬁ  ndings are supported by observations 
made by Ferrari et al who did not detect luciferase activity 
in the lungs of newborn rabbits after intratracheal instillation 
of linear PEI 22 kDa at N/P = 1.
Moreover, the kind of the solvent used for vector formula-
tion and delivery have an impact on gene transfer efﬁ  ciency 
and PEI/DNA complexes formulated in various solvents and 
applied to mouse lungs, seem to have a completely differ-
ent transfecting properties. After intratracheal instillation, 
in the mouse lung, complexes prepared in water express 
higher levels of transfection as compared to solvent like 
HBS (Rudolph et al 2000). One of the typical explanation 
for this phenomena is the fact that the colloidal stability of 
PEI/DNA complexes is very sensitive to the ionic strength 
of the surrounding solution and high salt concentrations, 
leading to salt-induced aggregation of complexes, make the 
transfection more difﬁ  cult. Interestingly, the solvent used to 
prepare the complexes could be important not only for the 
effect on the complexes structure itself but even for being 
directly effective on the airway epithelium. Rudolph and 
colleagues (2005b), using PEI/DNA complexes formulated 
in water and administered via aerosol, have shown that water 
is able to induce a permeabilization of the apical membrane 
as well as airway swelling and both these factors seem to be 
correlated with a better transfection efﬁ  ciency.
Since PEI exists as a branched polymer as well as in 
linear form, many in vivo experiments have been carried 
out to compare these two different structures. Efﬁ  ciency 
depends on the route of administration and on PEI molecular 
structure. In mice, both branched PEI 25 kDa and linear PEI 
22 kDa complexes formulated to have a N/P ratio of 5–10 
and administered through the trachea gave similar levels 
of lung luciferase expression although targeting different 
cell populations (Bragonzi et al 2000). On the other hand, 
Stammberger and colleagues showed that linear PEI 22 kDa 
determined higher luciferase activity than branched PEI 
25 kDa in ventilated lungs upon an intratracheal instillation 
in rats (Stammberger et al 2002).
Intranasal application of linear PEI 22 kDa polyplexes in 
mice has been shown to be superior to branched PEI 25 kDa 
vectors, yielding higher transgene expression (Wiseman et al 
2003). Branched PEI 25 kDa is more efﬁ  cient, when admin-
istered by aerosolization, as compared with both the linear 
PEI 22 kDa and the linear PEI 25 kDa (Rudolph et al 2005a). 
Linear PEI 25 kDa can produce large complexes aggregated 
whereas the linear PEI 22 kDa produce complexes which 
are very similar to those produced by branched PEI 25 kDa. 
These data indicate that particle aggregation seems not to 
inﬂ  uence gene delivery by PEI through aerosolization.
When the polyplexes are administered intravenously, lin-
ear PEI 22 kDa appears to be more efﬁ  cient than the branched 
PEI 25 kDa (Bragonzi et al 2000). Lung transfection using 
nonviral vectors via the intravenous route is mainly attributed 
to their physical properties that give rise to prolonged reten-
tion in the pulmonary circulation and efﬁ  cient interactions 
with the pulmonary vasculature (Song et al 1998; Li et al 
1999a). Linear PEI 22 kDa/DNA complexes share a similar 
mechanism in lung transfection. PEI/DNA complexes formu-
lated in 5% glucose and delivered into adult mice through the 
tail vein gave very high luciferase levels in the lung, at the 
level of endothelial cells of small vessels and penumocytes Drug Design, Development and Therapy 2008:2 175
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(Goula et al 1998a). At 2 h after injection large aggregates 
containing DNA were occasionally seen adhering to the wall 
of blood vessels (Goula et al 2000).
Organ DNA distribution and expression of plasmid DNA 
in vivo can be modulated signiﬁ  cantly via the selection of 
PEIs with different physicochemical properties, including 
molecular weight, structure, and PEI/DNA complexation 
ratios. Although different PEIs (branched 25 kDa, branched 
2 kDa, and linear 25 kDa) did not differ in prolonging the 
mean retention time of DNA in the blood as compared to 
naked DNA (Oh et al 2001; Jeong et al 2007), they deeply 
differed in organ distribution of the plasmid and its expres-
sion (Jeong et al 2007). Of the branched PEIs complexed 
with DNA at the same N/P ratio of 10, PEI 25 kDa showed a 
prolonged retention of plasmid DNA in the liver, as compared 
to PEI 2 kDa. At the same N/P ratio, linear PEI 25 kDa exhib-
ited lung plasmid DNA levels orders of magnitude higher 
than was seen with the branched 25 kDa until 3 days post-
dose. These results were paralleled by expression kinetics 
of plasmid DNA, with linear PEI 25 kDa providing mRNA 
expression levels order of magnitude higher in the lung than 
branched PEI 25 kDa over an 8-day period.
Finally, it has to be mentioned that efﬁ  ciency and lung 
speciﬁ  city of PEI-mediated delivery greatly depend upon 
the purity of the polymer (Thomas et al 2005). The removal 
of 11% residual acyl groups from the commercial linear 
25 kDa by acid hydrolysis at elevated temperature enhanced 
its plasmid DNA delivery effciency 21 times in vitro in A549 
cells and as much as 10,000 times in mice with a concomitant 
1500-fold enhancement in lung speciﬁ  city of gene delivery 
upon retroorbitally injection. To conﬁ  rm that the DNA 
transfection efﬁ  ciency of linear PEI is markedly affected 
by its extent of deacylation, three additional PEIs of 22-,87, 
and 217 kDa molecular weights were synthesized ab initio 
by acyl-catalyzed hydrolysis of poly(2-ethyl-2-oxazoline), 
yielding the pure polycations. PEI87 and PEI217 exhibited 
the highest DNA transfection efﬁ  ciency in vitro; moreover, 
PEI87 delivered DNA to the mouse lung as efﬁ  ciently as the 
pure PEI25 but at lower concentration and, importantly, with 
a 200-fold lung speciﬁ  city. Upon systemic delivery in mice 
of the complexes of a siRNA against a model gene, ﬁ  reﬂ  y 
luciferase, PEI25 and PEI87 afforded a 77% and 93%, respec-
tively, suppression of the gene expression in the lungs.
Persistence of gene expression
The persistence of transgene expression over the time is 
another important parameter to take in consideration as an 
ideal vector system should be able to confer a long duration 
of expression. Unfortunately, PEI/DNA complexes as well 
as the other non viral vectors are characterized by a poor 
persistence of gene expression. After intratracheal instillation 
of PEI/DNA complexes, the highest level of gene expression 
has been found after 24 h and a gradual decrease is observed 
over a time period of 7 days (Rudolph et al 2000). On the 
other hand, Gautam and colleagues (2001a) have shown that 
the transgene can be mantained for about 1 month follow-
ing aerosolization of polyplexes. This short length of gene 
expression holds true also in other organs. For example, 
PEI-mediated gene delivery to rat hypoglossal nuclei via 
intramuscular tongue injection lasted for only two weeks 
(Wang et al 2001).
The loss of transgene expression may be explained in one 
of several ways: loss of the vector, transcriptional silencing 
of the transgene promoter, loss of transfected cells through 
cell turnover, or the generation of immune response to trans-
gene product or the transfected cell itself. The majority of 
pre-clinical and clinical airway gene transfer studies have 
used strong viral promoters in order to achieve high-level 
gene expression in the lung. The human immediate-early 
cytomegalovirus (CMV) ehancer/promoter which is one of the 
most widely used, is known to undergo transcriptional inacti-
vation in several tissues, likely for the production of cytokines 
including TNFα and IFNγ (Kawakami et al 2006). Although 
not speciﬁ  cally used with PEIs, it is worth mentioning that 
several investigators have evaluated alternative promoters in 
the context of nonviral gene delivery to the lung, including 
the human ubiquitin (Gill et al 2001; Yew et al 2001) and the 
elongation factor 1α (Gill et al 2001), obtaining sustained (up 
to 6 months) gene expression in mice airways.
Given this short duration of expression, repeat dosing 
with no reduction in the level of PEI-mediated gene expres-
sion is an objective to be achieved. Wiseman and colleagues 
showed by means of intranasal administration of PEI 22 kDa 
complexes in mice that a second delivery seven days after the 
initial treatment only gives around 20% of the initial gene 
expression level (Wiseman et al 2003). This decrease was 
unlikely to be caused by antibody production against reporter 
gene product as it was still observed when the ﬁ  rst plasmid 
injected encodes a different protein, and in nude mice which 
cannot elicit T-cell dependent antibody response. Dames 
and colleagues using PEI 25 kDa, obtained fairly constant 
gene expression levels in mice lungs even 9 days after the 
ﬁ  rst PEI/DNA aerosol treatment although the third dose of 
PEI-DNA, which was administered 6 days after the ﬁ  rst dose, 
could not completely restore gene expression levels to the 
initial values (Dames et al 2006).Drug Design, Development and Therapy 2008:2 176
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In an attempt to further increase the level of transfection 
in the lung after an intravenous administration, Bragonzi 
et al observed that the administration of PEI 22 kDa/DNA 
complexes 16 h after the ﬁ  rst injection did not give any 
increase in transfection activity (Bragonzi et al 1999). On 
the contrary, when two injections of PEI 22 kDa complexes 
were administered at a 15-min interval, one log increase 
was observed. Orson et al using ternary complexes made 
of PEI-DNA and murine serum albumin (MSA) observed 
that repeated administration of the same dose of luciferase-
encoding plasmid did not increase the maximal detected 
activity, but did result in a relatively constant gene expression 
level, demonstrating that the response to repeated injection 
was not inhibited (Orson et al 2002). Similarly, we have 
observed that double intratracheal administration of com-
plexes made of PEI 25 kDa/DNA and MSA with a 3-day 
interval did not reduced luciferase expression in the lung but 
even increased its level (Di Gioia et al 2008).
An in vivo study with PEI-g-PEG demonstrated a pro-
longed gene expression in the spinal cord without experiencing 
any attenuation of gene expression after repeated intratechal 
injection of PEI-g-PEG/DNA complexes (Shi et al 2003). In 
contrast, 70% attenuation of the gene expression was observed 
after repeated administration of PEI/DNA complexes to the 
spinal cord at a 2-week interval. The attenuation was associ-
ated with apoptotic death, suggesting that PEGylation of PEI 
could have reduced intrinsic cytotoxicity of PEI.
With intravenous administration, reduced gene expres-
sion after a second dose was found to be related to induction 
of inﬂ  ammatory cytokines in response to unmethylated CpG 
motifs in the plasmid DNA (Li et al 1999b). Decreased gene 
expression following a second dose may also be due the toxic 
side effects associated with PEI, which have been reported 
following systemic injection of PEI /DNA complexes 
(Chollet et al 2002).
To overcome the limited transgene expression in the lung 
obtained with nonviral vectors, a new gene delivery vector 
based on the Sleeping Beauty (SB) transposase was used. 
The SB transposase is an enzyme that recognizes the ends of 
a transposon (indirect repeats, IRs), excises the transposon 
from its location in the genome, and reinserts it elsewhere 
into chromosomal DNA. By introducing a therapeutic gene 
between transposon IRs and supplying the transposase func-
tion, it is possible to use this transposon as a vector for gene 
therapy. Belur and colleagues demonstrated in the lungs of 
all animals transgene expression after 24 h after intrave-
nous injection with the luciferase transposon complexed to 
linear PEI 22 kDa, but expression up to 3 months required 
co-delivery of a plasmid encoding the SB transposase 
(Belur et al 2003). Transgene expression was localized to 
the alveolar region of the lung, with transfection of mainly 
type II pneumocytes.
The SB transposase/transposon system, however, medi-
ates integration at random sites in the genome and therefore 
could result in insertional mutagenesis similar to integrating 
viral vectors. Phage φC31 integrase is a site-speciﬁ  c recom-
binase that mediates efﬁ  cient integration of plasmid DNA 
into host cell genomes. It was demonstrated that integrase 
φC31 mediates site-speciﬁ  c integration in vitro and in vivo by 
recombining the attB recognition site in an episomal plasmid 
and one or more pseudo-attP sites in the host chromosome. 
This system has been tested in gene therapy approaches for 
different diseases, such ase hemophilia, epidermolysis bul-
losa, hereditay tyrosinemia type 1, and muscular dystrophy. 
Recently, Aneja and colleagues (2007) have shown expres-
sion of luciferase after intravenous injection of linear PEI 
22 kDa/DNA complexes could be observed after 2 weeks 
only in the lungs of mice which were co-injected with the 
integrase-encoding plasmid. Only seven out of the ﬁ  fteen 
treated mice showed integration in the mouse lung at the 
mpsL1 site at 8–9 months post-application, emphasizing the 
need for optimization of this sytem to maintain a sustained 
gene expression in the lung environment.
Localization of transfected cells 
in the lung
Many factors can inﬂ  uence the localization of PEI/DNA com-
plexes in the lung tissue, such as the route of administration 
or the type of PEI used. Diseases such as cystic ﬁ  brosis and 
asthma would need gene delivery to the airway epithelial cells 
of the conducting airways, whereas gene transfer into alveolar 
epithelial cells would be necessary to treat surfactant protein 
B deﬁ  ciency and α1-antitrypsin deﬁ  ciency. After injection 
of plasmid DNA formulated with PEI directly in the blood 
system, high levels of transgene expression can be found 
mostly in the lung alveolar tissue in mice (Goula et al 1998a, 
2000; Bragonzi et al 1999). These data have been conﬁ  rmed 
by means of electron microscopy which demonstrated how 
both type I and type II pneumocytes, as well as endothelial 
and myoepithelial cells can be transfected (Dif et al 2006). 
Levels and sites of expression are similar in normal and in 
CFTR-mutant mice. After intravenous administration, linear 
PEI 22 kDa complexes can transfect up to 5% of pulmonary 
cells (Zou et al 2000). Beta-galactosidase histochemistry 
conﬁ  rmed alveolar cells, including pneumocytes, to be the 
main target.Drug Design, Development and Therapy 2008:2 177
Polyethylenimines for lung gene therapy
After nebulization, gene expression is mainly localized in 
the bronchial epithelium of the large airways (Gautam et al 
2001a; Rudolph et al 2005a), and Rudolph and colleagues 
(2005a) argued that this kind of distribution could be due to 
a different rate of clearance of polyplexes by macrophages 
whose number is much higher in the alveoli than in the 
rest of respiratory tree. Recently, the same pattern of gene 
expression has been conﬁ  rmed using cell-speciﬁ  c antibod-
ies and GFP by intranasal instillation in mice (Davies et al 
2007). Bragonzi et al observed that, upon intratracheal 
instillation, both PEI 22 kDa and PEI 25 kDa had similar 
levels of transgene expression but that the pattern of tissue 
distribution was different with PEI 25 kDa complexes being 
distributed mainly in the large bronchi and PEI 22 kDa local-
ized in the distal tract of the broncho-alveolar tree (Bragonzi 
et al 2000).
In vivo toxicity
Though PEI is one of the most efﬁ  cient nonviral vectors, 
both its pronounced cellular toxicity and its severe systemic 
side effects as well as its pro-inﬂ  ammatory properties limit 
the use of PEI polyplexes for gene transfer in vivo. Several 
authors reported that PEI is able to induce multiple responses 
such as FasL-mediated antigen-induced apotosis (Regnstrom 
et al 2003), liver necrosis, activation of lung endothelium, 
adhesion of aggregated platelets and shock after systemic 
injection of elevated doses (Chollet et al 2002). Kawakami 
and colleagues (2006) observed that the intravenous admin-
istration of PEI/DNA complexes induced the production of 
serum proinﬂ  ammatory cytokines (TNF-α, interferon-γ, and 
interleukin-12), which are then reduced upon the administra-
tion of the linear PEI polyplexes as compared with that of 
branched PEI complexes.
In a recent study carried out by intratracheal instillation, 
the toxic effects of PEI-DNA and chitosan complexes have 
been analysed using a microarray platform (Regnstrom et al 
2006). Interestingly, PEI-DNA complexes seem to upregu-
late genes involved in inﬂ  ammatory processes, such as the 
cyclooxygenase 1 and 2, indicating possible involvement in 
the development of adverse reactions. Furthermore, genes 
involved in reaction to stress, such as chaperone genes and 
members of the p38 mitogen-activated protein kinase path-
way, were upregulated only in the PEI group, suggesting a 
possible explanation for the better performance of PEI than 
chitosan in gene delivery to the lung.
PEI polyplexes stimulate the immune system (Regnstrom 
et al 2003) and can cause from moderate to serious inﬂ  amma-
tion of lungs, which is evidenced by neutrophils inﬁ  ltration 
and reduced arterial oxygen saturation (Rudolph et al 2000). 
In contrast to these observations, transient inﬂ  ammation 
restricted to the lungs was observed by measurement of 
cytokine levels in the lungs, bronchoalveolar lavage ﬂ  uid, 
and serum when PEI gene vectors were applied via aerosol 
administration (Gautam et al 2001b).
Barriers to efﬁ  cient gene transfer 
to the lung
Direct instillation of PEI polyplexes would be needed in 
congenital and acquired lung diseases. In the lung, the 
mucus layer secreted by globet cells, apical membrane gly-
conjugates, and the airway epithelium with tight junctions 
inhibiting the intercellular transport remain the major barriers 
for efﬁ  cient topical nonviral-based gene delivery (Pilewski 
2002; Kolb et al 2006). Compared to PEI, the stability of 
TAT-PEG-PEI polyplexes was signiﬁ  cantly higher in the 
presence of high concentration of heparin, Alevofact® (a natu-
ral bovine surfactant preparation) as well as broncho-alveolar 
lavage ﬂ  uid, indicating that PEG-PEI complexes with DNA 
are endowed with increased complexation and condensation 
properties (Kleemann et al 2005).
In cystic ﬁ  brosis (CF), airways inspissated mucus and 
mucus plaques will enhance the barrier to airway gene 
transfer even further. The CF mucus, extremely thick and 
viscoelastic due to the presence of high amounts of DNA, 
proteins (albumin, actin and mucins), phospholipids, and 
inﬂ  ammatory products, is the primary barrier which induces 
a failure of viral and nonviral vectors in transducing airway 
epithelial cells (reviewed in (Ferrari et al 2002) and (Conese 
et al 2007)). While the exposure to surfactant proteins does 
not have any effect or even enhances PEI-mediated gene 
transfer (Ernst et al 1999), normal mucus has been found to 
inhibit gene delivery to native sheep tracheal epithelium main-
tained at an air-liquid interface (Ferrari et al 2001). Similarly, 
sputum and bronchoalveolar lavage ﬂ  uid (BALF) recovered 
from CF patients were demonstrated to inhibit PEI-mediated 
gene transfer efﬁ  ciency (Rosenecker et al 2003). Recently, 
we have shown that addition of human serum albumin (HSA) 
to preformed PEI/DNA complexes increased gene transfer 
efﬁ  ciency of PEI by 500–1000-fold in immortalized airway 
epithelial cells (Carrabino et al 2005). CF sputum inihibited 
PEI-mediated gene transfer, whereas in the presence of HSA, 
PEI showed increased levels of gene transfer. The presence of 
HSA in the complexes may have impeded interaction between 
positively charged PEI polyplexes and negatively charged 
albumin present in the CF sputum following increased vessel 
permeability due to chronic inﬂ  ammation.Drug Design, Development and Therapy 2008:2 178
Di Gioia and Conese
The role of bacteria infection in the gene transfer, 
speciﬁ  cally the massive colonization of CF airways by 
Pseudomonas aeruginosa and other bacteria, causes a pro-
found modiﬁ  cation in the airway “microenvironment” and 
this process must be taken into account when a nonviral 
vector is studied. Rejman and colleagues (2007), using mice 
infected by either P. aeruginosa or E. coli observed that the 
infection with P. aeruginosa caused a 5-fold increase in 
gene transfer whereas infection with E. coli had no effect. 
Moreover, by studying biodistribution of fluorescently 
labelled PEI-DNA complexes, the same group showed that 
prior treatment with P. aeruginosa increased penetration of 
the complexes deeper into the epithelium than in untreated 
animals. In P. aeruginosa-treated animals ﬂ  uorescence was 
detected not only in the airway epithelium itself but also in 
the parenchyma. They concluded that infection with P. aeru-
ginosa causes disruption of the tight junctions between the 
cells and thus of the barrier function of the epithelium. As a 
consequence, PEI-DNA complexes injected intratracheally 
into infected animals gain access to the basolateral side of the 
cells and to spaces across the epithelial lining, giving rise to 
substantially increased transfection efﬁ  ciency. These results 
strongly suggest that putative “receptors” for PEI/DNA 
complexes are not apically concentrated and indicate that, in 
the absence of bacterial infection, a targeting moiety should 
be added for efﬁ  cient transfection of bronchial/bronchiolar 
cells in vivo.
Pegylation and targeting of PEI 
polyplexes
The major limitations of positively charged PEI polyplexes 
include: limited efﬁ  ciency of gene delivery, toxicity at 
higher concentration, and potentially adverse interaction 
with negatively charged macromolecules in serum and cell 
surfaces (Plank et al 1996). Moreover, they can interact with 
the extracelullar matrix and nontarget cells. PEI polyplexes 
can be shielded by coating them with different compounds, 
among which the most used is polyethylene glycol (PEG) 
(Kircheis et al 2001; Lungwitz et al 2005; Park et al 2006) 
(Figure 4). PEI-PEG/DNA complexes, generated in 5% glu-
cose, have slightly reduced surface charge (∼20 vs ∼40 mV) 
and bigger size (125 vs 100 nm) as compared with PEI/DNA 
polyplexes (Kichler et al 2002) (Figure 2). A beneﬁ  cial effect 
of PEGylation that was observed is that the PEG-PEI conju-
gates are less cytotoxic than the nonmodiﬁ  ed polymers. This, 
however, may be related to the fact that less PEG-PEI/DNA 
complexes are uptaken by the cells (Kichler et al 2002). It 
was also found that PEG chains dramatically increase the 
solubility of the DNA complexes. At DNA concentration 
of 350 μg/ml, small precipitates were found when linear 
PEI 22 kDa was used at a N/P ratio of 12. In contrast, PEG-
PEI/DNA complexes with up to 1,500 μg/ml of DNA could 
be generated (Kichler et al 2002).
A hydrophilic shielding component, such as PEG, is intro-
duced into the complexes also to reduce aggregation (Sung 
et al 2003). For instance, while PEI polyplexes prepared in 
high ionic strenght medium (150 mM NaCl) showed a drastic 
increase in size due to aggregation, the TAT-PEG-PEI poly-
plexes remained stable over a period of 20 min (Kleemann 
et al 2005). However, polyplex aggregation under physi-
ological conditions is still an area of controversy and must be 
characterized thoroughly (Neu et al 2005). While aggregation 
of polyplexes in the lung vessels seems to be favorable for 
efﬁ  cient lung cell transfection, especially by linear 22 kDa 
PEI , this behavior may not be proﬁ  cient for transfection in 
distant sites (eg, cancer).
Targeting PEI polyplexes using peptides
Valid alternative approaches to PEGylation include the 
development of polyplexes displaying ligands for cellular 
receptors on their surface, the ligand having the additional 
effect of shielding positive charges. Different types of ligands 
such as sugar residues, growth factors, integrins, peptides, 
proteins and antibodies have been used for the targeting of 
PEI/DNA complexes in vivo (Kircheis et al 2001; Lungwitz 
et al 2005; Park et al 2006). In order to favorably modify the 
behavior of PEI/DNA complexes for systemic administra-
tion, different strategies have been developed to generate 
PEGylated ligand-PEI/DNA complexes (Figure 4).
Although several studies have ascertained that the 
conjugation of negatively charged ligands to PEI is suf-
ﬁ  cient to reduce the surface charge of PEI polyplexes, 
rendering not necessary the addition of PEG chains for 
this purpose (Kichler 2004), recent studies have shown 
that PEG-PEI-ligand complexes were used with success in 
targeting tumors and neurons using peptides (Table 2).
One group demonstrated that conjugates of branched PEI 
25 KDa PEGlyated with an RGD peptide vehicling siRNA 
inhibiting vascular endothelial growth factor receptor-2 
(VEGF-R2, also named KDR/ﬂ  k-1) was able to accumu-
late speciﬁ  cally in subcutaneously grown neuroblastoma 
N2A tumor, when administered intravenously, and medi-
ate inhibition of both tumor angiogenesis and growth rate 
(Schiffelers et al 2004). The same results were obtained 
when a conjugate of PEI grafted with PEG-RGD and a 
plasmid encoding the soluble form of VGF-R1 (ﬂ  t-1) was Drug Design, Development and Therapy 2008:2 179
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tested in the subcutaneous CT-26 adenocarcinoma model 
(Kim et al 2006b).
Targeting CD13 is an alternative strategy for speciﬁ  c 
targeting of cancers. It has been amply demonstrated that the 
CD13/aminopeptidase N protein is expressed exclusively on 
tumor cells, as well as endothelial cells of angiogenic tumor 
vasculature but not normal vasculature (Pasqualini et al 2000). 
Intravenous injection of a PEG/PEI/βgal vector harboring the 
CNGRC peptide, which binds speciﬁ  cally CD13, to nude 
mice bearing subcutaneous H1299 lung tumors resulted in as 
much as a 12-fold increase in β-gal expression in tumors as 
compared with expression in lungs. The CNGRC/PEG/PEI/
YFP vector targeted delivery to both tumor cells and tumor 
endothelial cells (Moffatt et al 2005). As a further reﬁ  nement, 
a multifunctional vector for p53-mediated gene therapy was 
created (Moffatt et al 2006). The SV40 large T peptide-NLS 
and oligonucleotide-based DNA nuclear targeting signal 
(DNTS) were coupled to the CNRGRC/PEG/PEI vector 
carrying the p53 gene in a EBV-based episomal system. This 
targeting vector was the most effective in reducing tumur 
volumes in the subctaneous H1299 tumor model as compared 
to the vector without NLS and DNTS coupling and increased 
animal survival up to 90% as opposed to only 20% with the 
untargeted PEI/DNA/β-gal vector.
PEI-mediated gene delivery to the central nervous system 
(CNS) of mice and rats using PEI/DNA complexes has been 
reported (Abdallah et al 1996; Goula et al 1998b; Wang et al 
2001; Li et al 2004). However, a certain toxicity (apoptosis) 
has been demonstrated after intracisternal administration of 
PEI/DNA complexes (Li et al 2004). To speciﬁ  cally target 
neurons, branched PEI 25 kDa was conjugated to two pep-
tides: the Tet1 peptide, which competes effectively with teta-
nus toxin for receptor binding to the neurons and neurotensin 
(NT), a 13-aminoacid neuropeptide. Targeted PEI complexes 
showed speciﬁ  c binding to differentiated PC-12 neuron-like 
cells but not to nonneuronal 3T3 ﬁ  broblasts (Park et al 2007). 
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Figure 4 Schematic representation of three strategies used for the formation of PEGylated ligand-containing PEI/DNA and PEI/siRNA complexes. (A) After PEGylation of 
PEI, the ligand reacts with functionalized distal end of the hydrophilic arm. The last step then consists of condensing the DNA/siRNA with the ligand-PEG-PEI conjugate. (B) 
PEI/DNA or PEI/siRNA complexes are ﬁ  rst generated. The resulted polyplexes are modiﬁ  ed by a heterobifunctional PEG which reacts with aminogroups of PEI. Ligands are 
ﬁ  nally incorporated into the complexes by conjugation with the distal end of the PEG. (C) The ﬁ  rst step consists of covalently coupling the ligand to PEI. Addition of plasmid 
DNA or siRNA leads to the formation of ligand-PEI/DNA(siRNA) complexes which are subsequently modiﬁ  ed with PEG chains. Modiﬁ  ed with permission from Kichler A. 
2004. Gene transfer with modiﬁ  ed polyethylenimines. J Gene Med, 6:S3–S10.Drug Design, Development and Therapy 2008:2 180
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Signiﬁ  cant binding to and uptake by primary neurons, derived 
from dorsal root ganglion isolated from embryonic mice, 
was only observed with Tet1-PEI formulations. However, 
since terminally differentiated neurons are not-dividing, 
gene expression was not observed under these conditions, 
indicating that Tet1-PEI formulation should be modiﬁ  ed with 
peptides that improve intracellular trafﬁ  cking. Since efﬁ  cient 
gene transfer to neurons was observed in vivo by application 
of untargeted PEI complexes to CNS via different delivery 
methods, it is also possible that Tet1 peptide affects PEI 
capability of transfecting differentiated neurons.
Table 2 summarizes the peptides used for guided PEI-
mediated gene delivery in vitro and in vivo, including those 
harboring binding, internalizing, endosome-destabilizing and 
nuclear import activities.
Targeting PEI complexes to the lung
As discussed above, PEI polyplexes transfect preferentially 
epithelial cells of the conducting airways if administered by 
intratracheal or aerosolization routes. Conversely, alveolar cells 
are preferably transfected with an intravenous admnistration. 
The airway epithelium of bronchi and bronchioli is the target 
for a successful gene therapy approach to cystic ﬁ  brosis (CF) 
and asthma, whereas the pulmonary endothelium and type I and 
II pneumocytes are the cell types to be transfected for treating 
pulmonary metastases, pulmonary hypertension, α1-antitrypsin 
deﬁ  ciency and surfactant deﬁ  ciency (Driskell and Engelhardt 
2003). Moreover, serous cells of airway submucosal glands 
express extremely high levels of the gene mutated in CF, ie, 
CFTR (Engelhardt et al 1992), suggesting that these regions 
may also be important gene therapy targets in CF.
Lac-PEI was investigated as a model for interaction with 
surface lectins (Fajac et al 2003; Grosse et al 2004; Grosse 
et al 2005). While in 70% conﬂ  uent undifferentiated human 
tracheal gland serous CF-KM4 cells, Lac-PEI is more efﬁ  -
cient than unsubstituted PEI and lactosylated polylysine 
in the presence of chloroquine, in differentiated CF-KM4 
and human bronchial epithelial cells grown as an explant-
outgrowth, a low gene transfer efﬁ  ciency was observed 
(Fajac et al 2003).
Recently, the function of lactoferrin as a novel targeting 
ligand for gene delivery to human airway epithelial cells 
has been investigated. Lactoferrin has been demonstrated to 
have many receptors on BEAS-2B bronchial epithelial cells 
(Ghio et al 1999) and not on A549 cells (type II pneumocytes) 
(Elﬁ  nger et al 2007). Interestingly, even with low degrees of 
lactoferrin coupling to branched PEI 25 kDa, the gene expres-
sion was about 5-fold higher than PEI alone in BEAS-2B cells. 
On A549 cells, no increase in gene expression was observed 
with lactoferrin/PEI complexes (Elﬁ  nger et al 2007).
To discover novel ligands, phage display libraries has 
been screened for peptide binding with high afﬁ  nity to airway 
epithelial cells. Romanczuk and colleagues (1999) found that 
the peptide SDQLASPYSHPR, coupled to an adenoviral 
vector using bifunctional PEG, increased gene transfer to 
well-differentiated human airway epithelial cells as compared 
to wild-type vector and to that bearing a scrambled peptide. 
Jost and colleagues (2001) used the peptide THALWHT, to 
deliver a luciferase reproter gene to conﬂ  uent 16HBE14o- 
bronchial cells, but obtaining only 10% of the levels reached 
by a liposomal gene transfer agent. Writer and colleagues 
(2004) found ﬁ  ve peptides which were incorporated into 
gene delivery formulations with the cationic lipid Lipofectin 
and shown to confer a high degree of transfection efﬁ  ciency 
and speciﬁ  city in 1HAEo- cells. The most efﬁ  cient peptide, 
LPHKSMP, consistently produced transfection efﬁ  ciencies 
around 10 times that obtained with the scrambled version of 
the peptide. Two peptides, RFDSLKV and GRGDGVD, were 
identiﬁ  ed by Vaysse and colleagues (2000) by biopanning on 
CFT-2, a human foetal tracheal cell line derived from a CF 
patient. The latter peptide contains an integrin-targeting RGD 
motif. When investigated in vivo upon systemic administration 
of peptides formulated with a cationic lipid, the peptide RFD-
SLKV determined an increase of lipid-mediated transfection 
of the lung (Vaysse et al 2002). Finally, Florea and colleagues 
(2003) identiﬁ  ed an internalizing peptide (CDSAFVTVDW-
GRSMSLC) which increased up to 6-fold PEI-mediated trans-
fection of differentiated human submucosal gland Calu-3 cells. 
Interestingly, confocal laser-scanning microscopy revealed 
basolateral localization in membrane-associated and inter-
nalizing vesicles. This pattern and the presence of a DGWR 
sequence in the peptide “receptor” that closely resembles the 
RGD motif, known to be recognized and constitutively inter-
nalized by α5β3 and α5β1 integrins (Parkes and Hart 2000), 
suggest that peptide endocytosis might be facilitated by an 
integrin receptor. Indeed, integrins have been considered as 
possible targets for receptor mediated gene delivery to airway 
epithelial cells (Meng et al 2004). However, caution should be 
used in interpreting this last study, since in vivo transfection 
of murine lung by intratracheal administration of Lipofectin/
integrin targeting peptide/DNA complexes showed a six-
fold enhancement of luciferase expression when lungs were 
pre-treated with EGTA, a Ca2+ −chelator able to disrupt tight 
juntions, indicating that nonviral vectors are able to transfect 
well diffeentiated polarized airway epithelial cells via integrin 
only when the basolateral membrane is exposed.Drug Design, Development and Therapy 2008:2 181
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An alternative strategy is to target known receptors and 
it has been successfully used in human CF airway epithelial 
cells and CF mice to correct primary and secondary defects 
due to CFTR mutations. Drapkin and colleagues (2000) found 
that human primary airway epithelial cells express the uroki-
nase receptor (uPAR) on the apical surface and that a peptide 
derived from the amino-terminal portion of uPA (CLNGGTC) 
is able to stimulate ﬂ  uid-phase endocytosis. Gene transfer of 
wild-type CFTR gene to CF airway epithelia by an adenoviral 
vector and correction of the cAMP-stimulated current was 
further enhanced in the presence of uPA Finally, coupling 
of the uPA peptide to the PEG-modiﬁ  ed adenoviral vector 
enhanced gene transfer to airway epithelia 10-fold. Ziady 
and colleagues (2002) administered molecular conjugates 
that contain a peptide (CSIPPEVKFNKPFVYLI) targeting 
the serpin-enzyme complex receptor and these beared the 
CFTR gene to the nasal epithelium of CF mutant mice. They 
observed partial correction of the chloride transport defect as 
assessed by in vivo nasal potential difference measurements 
and restoration of nitric oxide synthase-2, which is downregu-
lated in the epithelium of mice and humans with CF.
From a gene therapy standpoint, submucosal glands 
will most deﬁ  nitely be difﬁ  cult to target from the airway 
lumen. Several strategies have been proposed to circumvent 
this potential problem. One such method has utilized the 
polymeric IgA receptor to target DNA/protein complexes 
through the blood to glandular cells by transcytosis (Ferkol 
et al 1995, 2003).
Since the RGD peptide-containing polyplexes transfect 
preferentially angiogenic vasculature in tumors when admin-
istered intravenously (see above), alternative approaches must 
be found to target the pulmonary endotehelium and hence 
penumocytes in nonangiogenic conditions. One group has 
shown that a conjugate of linear PEI 22 kDa with antiplatelet 
endothelial cell adhesione molecule (PECAM) was 20-fold 
more efﬁ  cient than unconjugated PEI in tranfecting the mouse 
lung after an intravenous administration with lower toxicity 
with respect to circulating TNF-α levels (Li et al 2000).
PEI as potential nonviral vector 
for the treatment of lung diseases
Since PEI can achieve high levels of transgene expression in 
the lung, it could be potentially useful as therapeutic approach 
for many lung diseases such as cancer and asthma.
Cancer
The inhibition of tumor metastasis to the lung, which poses a 
huge challenge in most clinical settings, was one of the ﬁ  rst 
attempts carried out to study the function of PEI as nonviral 
vector. Many researchers reasoned that local delivery of 
agents via aerosol or intranasal instillation may offer a unique 
therapeutic opportunity. Intranasal or aerosol therapy delivers 
these agents directly to the lung, increasing the concentra-
tion in the tumor area and potentially decreasing systemic 
toxic effects.
Interleukin (IL)-12 is a cytokine that has antiangiogenic 
as well as immunostimolatory activity (Del Vecchio et al 
2007). IL-12 activates NK activity, facilitates the induction 
of cytotoxic and Th1 T cells, and stimulates the production 
of interferon-gamma. Many of these activities have been 
implicated in the antitumor effect of IL-12 (Brunda et al 
1993; Nastala et al 1994). Jia et al have demonstrated that 
PEI could be used to deliver the IL-12 gene to the mouse 
lung by both aerosol and intranasal administration, resulting 
in selective IL-12 expression with no spillover to the blood 
stream (Jia et al 2002, 2003). These investigators observed 
that mice that received PEI/IL-12, both intanasally and by 
aerosol twice weekly for 4–6 weeks, presented a decrease 
in the osteosarcoma lung metastases compared to the 
untreated mice. Interestingly, the same group observed that 
when IL-12, which is able to up-regulate Fas expression, 
was combined with one of the most used alkylating agents 
(ifosfamide), the therapeutic effect of this drug was enhanced 
(Duan et al 2006).
Another experimental approach to the anti-cancer therapy 
depends on the inhibition of growth and/or promotion of 
apoptosis of cancer cells. p53 codes for a nuclear phosphopro-
tein which is capable of modulating the expression of certain 
genes implicated in the regulation of cell division and apop-
tosis. The mutated p53 protein looses its anti-proliferative 
properties favoring a de-regulation of cellular multiplication 
with the accumulation of genetic aberrations. The delivery of 
p53 tumor suppressor gene complexed to PEI by aerosol can 
inhibit lung metastasis induced by a melanoma (Gautam et al 
2000) or by osteosarcoma cell line (Densmore et al 2001). 
Recently, it has been demonstrated that aerosol delivery of the 
PDCD4 gene (encoding for a protein that is able to decrease 
antiapoptotic protein BCL-XL, but increases the proapoptotic 
proteins such as BAX, BAD, BID as well as inhibiting the 
synthesis or activation of AP-1 protein) might be a useful 
system in anti-cancer therapy of lungs. This study suggests 
that combined actions such as facilitating apoptosis, control-
ling cell cycle and suppression of AP-1 activity by PDCD4 
may provide useful tool for designing lung tumor prevention 
and treatment by which PDCD4 functions as a transformation 
suppressor in the future (Hwang et al 2007).Drug Design, Development and Therapy 2008:2 182
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Lung transplantation
The treatment of acute and chronic airway injury caused by 
immune response in particular conditions, such as the lung 
transplantation, is another important ﬁ  eld of application 
of PEI-mediated gene therapy. Using PEI as nonviral vec-
tor and a SB transposase/transposon system encoding the 
human gene indoleamine-2, 3-dioxygenase (hIDO), which 
is an enzyme that possesses both T cell-suppressive and anti-
oxidant properties, Liu and colleagues have demonstrated that 
a single dose of intratracheal-administered hIDO-expressing 
transposon complexed with PEI is effective in preventing the 
development of lung allograft ﬁ  brotic injury as well as the 
ischemia-reperfusion injury, in rats (Liu et al 2006, 2007). It 
is noteworthy that the high level of lung IDO activity cannot 
be achieved by giving animals this enzyme directly, as stable 
and puriﬁ  ed protein is not available at the present. Moreover, 
this novel pharmacological intervention may be usful in 
most lung diseases characterized by ﬁ  brosis with impaired 
pulmonary function such as asthma, cystic ﬁ  brosis, idiopathic 
pulmonary ﬁ  brosis and pulmonary hypertension.
Asthma
Another application of PEI polyplexes, where local delivery 
can be successfully made, is asthma. Seong and colleagues 
generated antisense oligodeoxynucleotides (AS-ODNs) 
against murine IL-4 mRNA as IL-4 plays a crucial role as 
an inﬂ  ammatory mediator in allergic asthma via inducing 
Th2 inﬂ  ammation and IgE synthesis. When administered 
intranasally, the IL-4 AS-ODNs/PEI complexes were capable 
of inhibiting IL-4 secretion in a sensitized murine model of 
airway inﬂ  ammation (Seong et al 2006).
RNA interference
RNA interference (RNAi), the mechanism by which the 
expression of a speciﬁ  c protein can be reduced or eliminated, 
has emerged as a potential therapeutic agent for treating 
numerous diseases, including cancer and other diseases 
from genetic disorders to viral infection (de Fougerolles 
et al 2007). RNAi pathways are guided by small RNAs that 
include small-interfering RNAs (siRNAs) and microRNAs, 
the latter being called the ‘endogenous’ pathway. In gene 
delivery, it is possible to harness the endogenous pathway 
in one of two ways: either by using a viral vector to express 
short hairpin RNA (shRNA) that resembles microRNA pre-
cursors, or by introducing siRNAs that mimic the cleavage 
product into the cytoplasm.
PEI-siRNA complexes have been reported to be efﬁ  cient 
in vitro and to show therapeutic beneﬁ  t in vivo in a number 
of disease models. In Table 1, we report selected examples 
referred to cancer and infectious diseases. Since the applica-
tion of PEI/siRNA to tumors has already been described in 
other sections of this review, we focus here on respiratory 
infectious diseases, which are one of the main targets of 
nonviral delivery of siRNAs by polycationic polymers to the 
lung (Thomas et al 2007). To this end, several groups have 
been optimizing the physical structure of PEI to improve in 
vivo siRNA delivery (Thomas et al 2005; Grayson et al 2006; 
Werth et al 2006). Ge et al have shown that short siRNAs 
speciﬁ  c for conserved regions of inﬂ  uenza virus genes, espe-
cially those encoding nucleocapsid protein (NP), can prevent 
and treat inﬂ  uenza virus infection in mice (Ge et al 2004). 
In this study, virus production in lungs of infected mice was 
reduced by siRNAs given either before or after virus infec-
tion, by using slow iv administration of small volumes con-
taining siRNAs in complexes with PEI. Interestingly, these 
results have been conﬁ  rmed by another study which showed 
that retroorbitally administered PEI-NP siRNA resulted in 
94% drop of virus titers in the lungs of inﬂ  uenza-infected 
animals (Thomas et al 2005). It is noteworthy to mention 
that previous vaccine development studies have shown that 
even a 90% reduction in the virus titer leads to the survival 
from a lethal challenge (Epstein et al 2002).
Clinical application of PEI-mediated 
gene delivery
The versatility and efﬁ  ciency of PEI-based gene transfer 
to the lung in different in vivo settings warrants further 
investigation in terms of possible therapeutic applications. 
The following steps have to be considered for moving PEI 
into the clinic:
1)  If gene delivery agents are to be considered a drug, a 
stable formulation is an essential requisite. In acqueous 
solution, nonviral delivery systems suffer from poor 
long-term physical stability including the loss of transfec-
tion efﬁ  cacy and the tendency to aggregate. It has been 
shown that lyophilization of PEI complexes may under 
certain conditions prevent these effects leading to the 
preservation of physical stability and biological activity 
for DNA (Talsma et al 1997; Brus et al 2004) and siRNA 
(Werth et al 2006). Importantly, a controlled degradation 
to intracellualar nontoxic products has to be included to 
tackle cytotoxicity. Hence, the use of biodegradable PEIs 
should be pursued.
2)  The type of lung disease and the cell type(s) to be targeted 
deﬁ  nes which route of administration and the type of 
polyplexes should be used. Intravenous injection “target” Drug Design, Development and Therapy 2008:2 183
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primarly the lung and achieve high transfection levels in 
alveolar cells. Chemical modiﬁ  cations with hydrophilic 
residues to avoid interactions with ionic macromolecules 
(such as PEG) and grafting with cell-speciﬁ  c ligands 
or antibodies are the current strategies to increase lung 
speciﬁ  city. Indeed, transgene expression in nontarget 
cells could lead to side-effects. In particular, the uptake 
of pDNA by immune cells is a major obstacle to nonviral 
gene therapy approaches, because the uptake sometimes 
triggers a severe immune reaction which reduces the 
level and duration of transgene expression in target 
cells. Aerosolization is the preferred method for topi-
cal delivery of PEI/DNA complexes that results in the 
higher efﬁ  ciency/toxicity ratio. However, cilia beating 
and mucociliary clearance can be difﬁ  cult hurdles to be 
overcome. Thus, the local conﬁ  nement of nucleic acid 
delivery is an important requirement for gene delivery to 
the airway epithelium. Magnetofection is a novel tech-
nique which could guide aerosols to speciﬁ  c regions of 
the lung using an external magnetic ﬁ  eld (Plank 2008).
3)  Although toxic and immunological reactions are lower 
than those elicited by cationic lipids and viral vectors, 
they are not fully absent. This is due to the bacterial nature 
of plasmid DNA, rich in CpG motifs, a constraint which 
can be overcome by using plasmid with no such motifs 
(Yew et al 2002). The potential of PEI for stimulating 
immune response when complexed with siRNA has not 
yet been studied. However, it is known that RNA mol-
ecules less than 20 bp in length are generally believed to 
avoid induction of interferon pathways (Fish and Kruithof 
2004).
4)  Gene therapy approaches for genetic or acquired disorders 
(such as cystic ﬁ  brosis or asthma) requires long-term 
and sustained transgene expression levels in vivo. This 
is not available with PEIs and the currently used genetic 
material, although some studies are currently evaluating 
the use and optimization of site-spciﬁ  c integrase (Aneja 
et al 2007).
5) In terms of lung disease which could potentially be 
cured by PEI-mediated gene delivery, those targeted by 
intravenous route of administration are likely to be the 
ﬁ  rst, including This category includes cancer (primary 
or metastatic) and alveolar-borne diseases, such as acute 
respiratory distress syndrome.
Conclusion
In the present review, we have illustrated some of the interest-
ing features of PEI-mediated gene delivery and barriers which 
impede its clinical application at the levels of organ, tissues 
and cells. Proof-of-principle that PEI can have therapeutic 
effect in both genetic and acquired lung diseases has been 
given. However, speciﬁ  c studies aimed to overcome some 
of the extracellular barriers (eg, mucus) have not been per-
formed, reﬂ  ecting the absence of appropriate animal models. 
Only when these caveats will be addressed, can therapeutic 
use of PEIs become a reality.
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